Legend Biotech’s 93/100 Growth Score Collides With a Stock Near Two-Year Lows

Legend Biotech Corporation is putting up some of the strongest revenue growth numbers on the entire watchlist, yet its shares are sitting near the bottom of their two-year range. That gap between fundamental momentum and market price is the story at the center of this Legend Biotech stock analysis: a company scoring 93 out of 100 on Growth while the market assigns it just 26 out of 100 on Opportunity.

What Is Happening With the Stock Price

Shares currently trade at $22.60, well down from a two-year high of $57.55 and only modestly above the two-year low of $16.80. That puts the stock at roughly 14% of the way up its two-year range – firmly in lower-end territory. A stock priced this close to its floor typically signals that the market has grown skeptical of the growth story playing out in the numbers, or is discounting risks not fully visible in the headline figures.

Quality: Is This a Financially Sound Business?

The Quality picture is mixed, which is common for a biotech still scaling a commercial product. Gross margin sits at a healthy 56.6%, and operating margin is positive at 14.9% – evidence the core business, once revenue reaches the income statement, is not fundamentally cost-inefficient. Yet net profit margin is negative at -7.2%, with return on equity of -8.1% and return on assets of -1.9%. That divergence between a positive operating margin and a negative net margin points to meaningful costs below the operating line dragging profitability down. Cash generation is thin but real: free cash flow of $15M on revenue of $1.3B works out to a 0.3% FCF yield – barely positive, not a cushion investors should lean on. Balance sheet strength partly offsets this: a current ratio of 3.04 and quick ratio of 2.39 indicate ample short-term liquidity, and debt-to-equity of just 0.23 means the company isn’t leaning on leverage to fund operations.

Growth: Does This Company Have Real Upside?

This is where the Legend Biotech stock analysis gets interesting. Revenue grew 51.9% over the trailing twelve months, and the five-year revenue CAGR stands at 106.4% – a scale of sustained expansion that few names on the watchlist can match. Despite that trajectory, the stock trades at just 2.68x EV/Revenue, a modest multiple for a company growing at this pace. Earnings growth over the trailing twelve months is not available, reflecting the company’s still-unprofitable bottom line even as the top line scales rapidly.

Opportunity: Is Now a Good Time to Enter?

Opportunity is where the model turns cautious, scoring just 26 out of 100. With no P/E ratio available (earnings per share is -$0.50), the model can’t use earnings-based valuation as a gauge, and price-to-book at 3.44 doesn’t scream cheap for a business still posting negative returns on equity. The stock’s position low in its two-year range might look like an entry opportunity on price alone, but the model’s low Opportunity score reflects that this discount hasn’t been earned through demonstrated valuation support – it’s a growth story trading on hope for margin inflection rather than proven earnings power.

Legend Biotech Corporation Stock Analysis: The Bottom Line

Legend Biotech presents a genuine tension: best-in-class revenue growth (93/100) paired with a valuation picture the model isn’t ready to endorse (26/100), landing the overall Recommendation Score at 58/100 and a Hold signal. This reflects StreetBriefs’ quantitative scoring model – a data-driven signal for further research, not a personalized recommendation to transact. The bull case rests on continued triple-digit-adjacent revenue expansion eventually translating into sustainable operating profitability; the bear case is that a company still posting negative net margins and a thin 0.3% FCF yield could see further downside if growth decelerates before profitability arrives. Investors researching this Legend Biotech stock analysis should weigh the strong balance sheet liquidity against the real risk that earnings power remains unproven. This analysis is based on Yahoo Finance data as of August 20, 2026, and is for informational purposes only – not investment advice. Data may be delayed or contain errors; always do your own due diligence or consult a licensed financial advisor before making investment decisions.